BR112021024886A2 - Métodos de tratar a doença de fabry em pacientes com insuficiência renal - Google Patents
Métodos de tratar a doença de fabry em pacientes com insuficiência renalInfo
- Publication number
- BR112021024886A2 BR112021024886A2 BR112021024886A BR112021024886A BR112021024886A2 BR 112021024886 A2 BR112021024886 A2 BR 112021024886A2 BR 112021024886 A BR112021024886 A BR 112021024886A BR 112021024886 A BR112021024886 A BR 112021024886A BR 112021024886 A2 BR112021024886 A2 BR 112021024886A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- methods
- renal failure
- patients
- treating fabry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024886A2 true BR112021024886A2 (pt) | 2022-01-25 |
Family
ID=71950725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024886A BR112021024886A2 (pt) | 2019-06-11 | 2020-06-11 | Métodos de tratar a doença de fabry em pacientes com insuficiência renal |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (https=) |
| EP (1) | EP3982962A1 (https=) |
| JP (2) | JP7677910B2 (https=) |
| KR (1) | KR20220019796A (https=) |
| CN (1) | CN114423427A (https=) |
| AR (1) | AR120055A1 (https=) |
| AU (2) | AU2020291002A1 (https=) |
| BR (1) | BR112021024886A2 (https=) |
| CA (1) | CA3141226A1 (https=) |
| CL (1) | CL2021003280A1 (https=) |
| EA (1) | EA202290024A1 (https=) |
| IL (1) | IL288677A (https=) |
| MX (1) | MX2021015352A (https=) |
| PH (1) | PH12021553102A1 (https=) |
| TW (1) | TW202112372A (https=) |
| WO (1) | WO2020252129A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| MX2009011473A (es) * | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| SG10201604757RA (en) * | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| CA3224546C (en) * | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| RS65230B1 (sr) * | 2017-05-30 | 2024-03-29 | Amicus Therapeutics Inc | Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega |
-
2020
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko active Pending
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en not_active Abandoned
- 2020-06-11 JP JP2021573404A patent/JP7677910B2/ja active Active
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en not_active Ceased
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 PH PH1/2021/553102A patent/PH12021553102A1/en unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
-
2025
- 2025-05-01 JP JP2025076158A patent/JP2025131572A/ja active Pending
-
2026
- 2026-01-29 AU AU2026200618A patent/AU2026200618A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026200618A1 (en) | 2026-04-16 |
| WO2020252129A1 (en) | 2020-12-17 |
| IL288677A (en) | 2022-02-01 |
| CN114423427A (zh) | 2022-04-29 |
| EP3982962A1 (en) | 2022-04-20 |
| PH12021553102A1 (en) | 2023-10-09 |
| CL2021003280A1 (es) | 2022-10-07 |
| KR20220019796A (ko) | 2022-02-17 |
| US20220313670A1 (en) | 2022-10-06 |
| CA3141226A1 (en) | 2020-12-17 |
| JP2025131572A (ja) | 2025-09-09 |
| AR120055A1 (es) | 2022-02-02 |
| AU2020291002A1 (en) | 2022-01-06 |
| MX2021015352A (es) | 2022-04-06 |
| JP7677910B2 (ja) | 2025-05-15 |
| TW202112372A (zh) | 2021-04-01 |
| EA202290024A1 (ru) | 2022-03-14 |
| JP2022536687A (ja) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
| Khandelwal et al. | Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients | |
| Barroso et al. | Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years | |
| MX391565B (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| Brown et al. | NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| Zhang et al. | The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| Rauck et al. | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies | |
| BR112023020626A2 (pt) | Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| BR112015023806A2 (pt) | Novos regimes de dosagem de celgosivir para o tratamento de dengue | |
| BR112022009510A2 (pt) | Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição | |
| Deodhar et al. | THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials | |
| Wang et al. | Successful extracorporeal membrane oxygenation resuscitation of patient with cardiogenic shock induced by phaeochromocytoma crisis mimicking hyperthyroidism: a case report | |
| BR112014029302A2 (pt) | método de redução de peso | |
| De Stefano et al. | A breathe in cystic fibrosis therapy: a new therapeutic endeavor for cysteamine | |
| BR112018017167A2 (pt) | titulação de cebranopadol | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| Braun et al. | AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |